KL‐6 Mucin as Serum Tumor Marker of Metastatic Renal Cancer: A Case Report.

We encountered a case of metastatic renal cell carcinoma in which the serum level of KL‐6, a therapeutic marker, was exceptionally high and fluctuated with the progression of treatment. A 74‐year‐old man was diagnosed with right renal cystic cancer and multiple metastases in October 2022. The KL‐6 level was 27490 U/mL. He started treatment with lenvatinib and pembrolizumab. KL‐6 decreased to 3885 U/mg in February 2023. The patient's proteinuria worsened, leading to the discontinuation of lenvatinib. KL‐6 increased to 25950 U/mL in April. He discontinued pembrolizumab and started taking cabozantinib. In September, drug‐induced bilateral inflammatory pneumonitis developed. He discontinued cabozantinb and began taking axitinib. KL‐6 decreased; however, he suffered from severe diarrhea and subsequent renal insufficiency. He discontinued axitinib in November. KL‐6 increased to 29640 U/mL in December. [ABSTRACT FROM AUTHOR]